Biomatrix, Rhône-Poulenc Rorer Canada Inc. deal

RPR Canada received exclusive Canadian rights for up to 15 years for BIOX's Synvisc (hylan G-F 20) therapeutic for osteoarthritis. RPR Canada paid a $3.5 million licensing fee, and will pay a $2 million fee after achieving certain sales volume.

RPR Canada will cover the cost of BIOX's sales and customer service organizations, which will continue to support Synvisc in Canada in conjunction with the pharma company. The agreement increases to 46 from eight the number of direct salespeople responsible for selling the product in Canada. BIOX (Ridgefield, N.J.) will manufacture the product. ...